LB Pharmaceuticals Inc
NASDAQLB Pharmaceuticals enters the final stretch before its August 11 earnings with a striking divergence: the Street is growing more constructive, while nearly one-in-five shares of the float remain in short hands. The most notable development this week is fresh analyst coverage from BMO Capital, which initiated on July 21 with an Outperform rating and a $46 target. That follows Wolfe…
LBRX short interest surges 25.4% in one week to 14.9% of float, as cost to borrow plummets 28% amid upcoming earnings call.
Snapshot as of 9 Aug 2026
LB Pharmaceuticals enters the final stretch before its August 11 earnings with a striking divergence: the Street is growing more constructive, while nearly one-in-five shares of the float remain in short hands. The…
LBRX heads into today's print with a sharp build in short positioning — the clearest pre-earnings signal on this name. Short interest has risen aggressively. At nearly 15% of the free float (ORTEX estimates 19.3% on…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LBRX — free to start on ORTEX.
Sign up for free →Open LBRX on ORTEX